Synchron
Synchron is a neurotechnology company located in Brooklyn, New York. It focuses on developing implantable Brain-Computer Interfaces (BCIs) that aim to restore and protect human agency without the need for open-brain surgery. The company is known for creating interventional brain-computer interfaces to provide neural solutions for millions of individuals. The primary product, Stentrode™, is a minimally invasive motor neuroprosthesis that is implanted through the jugular vein using a catheter-based procedure. Clinical trials in the USA and Australia are evaluating Stentrode's effectiveness in helping people with paralysis regain communication and control over digital devices using their thoughts. Additionally, Synchron is working on endovascular neuromodulation devices to address neurological conditions such as Parkinson’s disease, epilepsy, depression, and hypertension. Founded in 2016 by Thomas Oxley and Nicholas Opie, Synchron operates in the Medical Equipment Manufacturing and Therapeutic Devices sectors. The company aims to restore, extend, and protect human agency through innovative catheter-delivered electronics.